caa a22 4500 397593368 CHVBK 20180308164945.0 cr unu---uuuuu 161202e199611 xx s 000 0 eng 10.1093/jac/38.5.819 doi (NATIONALLICENCE)oxford-10.1093/jac/38.5.819 Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model [Elektronische Daten] [E. A. Petersen, J. B. Grayson, E. M. Hersh, R. T. Dorr, S.-M. Chiang, M. Oka, R. T. Proffitt] Disseminated Mycobacterium avium complex (MAC) infection has reached epidemic proportions and is a major cause of morbidity and mortality in AIDS patients. We have developed a liposomal preparation of amikacin, VS107, which incorporates the drug in 54-65 nm diameter unilameller phospholipid vesicles and is stable at 4°C for more than 4 months. VS107 exhibits superior microbiological and pharmacological activity over the free amikacin and improves the survival of mice in the established model for MAC infection. The serum half-life of VS107 in mice was 9.1 h and a peak serum level of 730 mg/L was obtained after administering three doses of 160 mg/kg. For the therapeutic study, beige mice infected with 107 cfu M. avium complex strain 101 were randomised to be treated with placebo liposomes, buffer, free amikacin or VS107 The drugs were administered via the caudal vein thrice weekly for 1, 3, 5 or 7 weeks beginning 5 days after infection. After 51 days of treatment with VS107, the number of viable M. avium in the liver and spleen was a 100 fold lower than was achieved with conventional amikacin (P < 0.01), and more than six decimal logarithms lower than was found untreated controls (P < 0.001). VS107 was well tolerated and might be a suitable candidate for treating human MAC infections. © 1996 by the British Society for Antimicrobial Chemotherapy Original articles nationallicence Petersen E. A. Department of Medicine, University of Arizona College of Medicine and Arizona Cancer Center 1501 N. Campbell Ave., Tucson, AZ 85724 Grayson J. B. Department of Medicine, University of Arizona College of Medicine and Arizona Cancer Center 1501 N. Campbell Ave., Tucson, AZ 85724 aut Hersh E. M. Department of Medicine, University of Arizona College of Medicine and Arizona Cancer Center 1501 N. Campbell Ave., Tucson, AZ 85724 aut Dorr R. T. Department of Medicine, University of Arizona College of Medicine and Arizona Cancer Center 1501 N. Campbell Ave., Tucson, AZ 85724 aut Chiang S.-M NeXtar Pharmaceuticals, Inc. 650 Cliffside Dr., San Dimas, CA, USA aut Oka M. NeXtar Pharmaceuticals, Inc. 650 Cliffside Dr., San Dimas, CA, USA aut Proffitt R. T. NeXtar Pharmaceuticals, Inc. 650 Cliffside Dr., San Dimas, CA, USA aut Journal of Antimicrobial Chemotherapy Oxford University Press 38/5(1996-11), 819-828 0305-7453 38:5<819 1996 38 jac https://doi.org/10.1093/jac/38.5.819 text/html Onlinezugriff via DOI 1 other jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/38.5.819 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Petersen E. A. Department of Medicine, University of Arizona College of Medicine and Arizona Cancer Center 1501 N. Campbell Ave., Tucson, AZ 85724 NATIONALLICENCE 700 1- Grayson J. B. Department of Medicine, University of Arizona College of Medicine and Arizona Cancer Center 1501 N. Campbell Ave., Tucson, AZ 85724 aut NATIONALLICENCE 700 1- Hersh E. M. Department of Medicine, University of Arizona College of Medicine and Arizona Cancer Center 1501 N. Campbell Ave., Tucson, AZ 85724 aut NATIONALLICENCE 700 1- Dorr R. T. Department of Medicine, University of Arizona College of Medicine and Arizona Cancer Center 1501 N. Campbell Ave., Tucson, AZ 85724 aut NATIONALLICENCE 700 1- Chiang S.-M NeXtar Pharmaceuticals, Inc. 650 Cliffside Dr., San Dimas, CA, USA aut NATIONALLICENCE 700 1- Oka M. NeXtar Pharmaceuticals, Inc. 650 Cliffside Dr., San Dimas, CA, USA aut NATIONALLICENCE 700 1- Proffitt R. T. NeXtar Pharmaceuticals, Inc. 650 Cliffside Dr., San Dimas, CA, USA aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 38/5(1996-11), 819-828 0305-7453 38:5<819 1996 38 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford